OncRef

Clinical Trial: NCT06400472

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

Status:

RECRUITING

Phase:

Phase 1

Lead Sponsor:Eli Lilly and Company
Information Provided By:Eli Lilly and Company
Last Update Posted:2026-11-04

Study Overview

Brief Summary

The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in three parts - phase Ia (dose-escalation, dose-optimization), phase Ib (dose-expansion), and phase 2 (dose expansion). The study will last up to approximately 5 years.

Official Title

A First-in-Human, Phase 1/2 Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Sofetabart Mipitecan (LY4170156), an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors

Conditions

Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms

Intervention / Treatment

  • Drug: Sofe-M
  • Drug: bevacizumab
  • Drug: carboplatin
  • Drug: Itraconazole
  • Drug: pembrolizumab

Other Study ID Numbers

  • 18863
  • 2024-511238-11-00
  • J5E-OX-JZXA
  • LOXO-FRA-24001

Start Date (Actual)

2024-05-20

Primary Completion Date (Estimated)

2029-06

Study Completion Date (Estimated)

2029-06

Enrollment (Estimated)

575

Study Type

Interventional

Phase

Phase 1